Entrada Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(122,222) | $(104,586) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 2,316 | 3,210 |
| Stock‑based compensation expense | 14,672 | 15,251 |
| Amortization/(accretion) of marketable securities | (1,255) | (3,038) |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable | 339 | 2,484 |
| Prepaid expenses and other current assets | (382) | 6,138 |
| Right-of-use assets, operating leases | 5,153 | 8,998 |
| Other non-current assets | (53) | 121 |
| Accounts payable | 2,576 | (922) |
| Accrued expenses and other current liabilities | (1,403) | 2,592 |
| Income tax payable | — | (47) |
| Operating lease liabilities | (3,619) | (6,807) |
| Deferred revenue | (244) | (19,703) |
| Net cash used in operating activities | (104,122) | (96,309) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (216) | (1,248) |
| Purchases of marketable securities | (23,666) | (123,140) |
| Maturities of marketable securities | 148,740 | 212,077 |
| Net cash provided by investing activities | 124,858 | 87,689 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 130 | 378 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 320 | 317 |
| Net cash provided by financing activities | 450 | 695 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 21,186 | (7,925) |
| Cash, cash equivalents, and restricted cash at beginning of period | 94,344 | 105,161 |
| Cash, cash equivalents, and restricted cash at end of period | $115,530 | $97,236 |
| Supplemental cash flow disclosures: | ||
| Vesting of options early exercised subject to repurchase | $— | $14 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.